BioInformant

Your Global Leader in Stem Cell Market Research

Home » BioCardia

Stem Cells for Heart Failure? BioCardia’s CardiAMP Pairs Cells, Devices and Diagnostics

By 1 Comment

Circulation Research, the official journal of the American Heart Association, has highlighted a novel stem cell therapy approach developed by BioCardia. For those not familiar with BioCardia, the company specializes in developing regenerative biologic therapies to treat cardiovascular disease.

BioCardia has developed a stem cell technology that includes a novel method of administration, as well as a pre-procedure assay to achieve a comprehensive approach to heart failure. BioCardia’s CardiAMP and CardiALLO cell therapies are the Company’s biotherapeutic product candidates in clinical development.

In addition to providing Phase III 10-patient roll-incohort data for BioCardia’s CardiAMP device, the paper published by Circulation Research offers a comprehensive rationale of CardiAMP’s development as a treatment for heart failure. [Read more…]

Preliminary Results From BioCardia’s Phase III Pivotal CardiAMP Heart Failure Trial Reported In Circulation Research Journal

By Leave a Comment

BioCardia - CardiAMP Heart Failure Trial SAN CARLOS, Calif., Aug. 22, 2018 — In a Viewpoint paper published online today in Circulation Research, the Phase III CardiAMP Heart Failure Trial (CardiAMP-HF Trial) studying the investigational CardiAMP stem cell therapy from BioCardia®, Inc. (OTC: BCDA) was highlighted as an example of personalized medicine, with promising results from the first 10 patients in the roll-in cohort reported. The company believes this to be the first outcomes data published from any pivotal trial of a stem cell therapy for heart failure. The paper is authored by Peter Johnston, M.D., Eric Duckers, M.D., Ph.D., Amish Raval, M.D., Thomas Cook, Ph.D. and Carl Pepine, M.D. [Read more…]

BioInformant's World-Class Clients